Treatment of bone disorders with parathyroid hormone: Success and pitfalls
Bone diseases such as osteoporosis, osteoarthritis, bone tumours and bone fractures are rather common and not just in the elderly. Parathyroid hormone (PTH) is responsible for maintaining calcium homeostasis, increasing bone mineral density (BMD), increasing cortical and trabecular bone thickness an...
| Main Authors: | , , , |
|---|---|
| Format: | Journal Article |
| Published: |
Govi Verlag Pharmazeutischer Verlag GmbH
2016
|
| Online Access: | http://hdl.handle.net/20.500.11937/34660 |
| _version_ | 1848754283634229248 |
|---|---|
| author | Ng, P. Ong, A. Gale, L. Dass, Crispin |
| author_facet | Ng, P. Ong, A. Gale, L. Dass, Crispin |
| author_sort | Ng, P. |
| building | Curtin Institutional Repository |
| collection | Online Access |
| description | Bone diseases such as osteoporosis, osteoarthritis, bone tumours and bone fractures are rather common and not just in the elderly. Parathyroid hormone (PTH) is responsible for maintaining calcium homeostasis, increasing bone mineral density (BMD), increasing cortical and trabecular bone thickness and thus increasing bone strength. Teriparatide (PTH 1-34) has the same effects as endogenous PTH and is pharmacologically used to treat bone diseases such as osteoporosis, osteoarthritis, bone fractures and bone tumours. This review discusses how PTH 1-34 plays a role in managing bone diseases. Clinical studies have shown that short or intermittent dosing of PTH 1-34 has minimal adverse effects, while long-term dosing (over two years) has been linked to de novo osteoarthritis and bone deformation. Currently PTH therapy is only approved in the treatment of post-menopausal osteoporosis, however it is also proven to have effects in treating osteoarthritis, bone tumours and bone fractures. If the patient undergoing therapy is closely monitored, the major pitfalls are very unlikely to take place, thus it is highly recommended that patients be closely monitored by a medical practitioner. |
| first_indexed | 2025-11-14T08:37:57Z |
| format | Journal Article |
| id | curtin-20.500.11937-34660 |
| institution | Curtin University Malaysia |
| institution_category | Local University |
| last_indexed | 2025-11-14T08:37:57Z |
| publishDate | 2016 |
| publisher | Govi Verlag Pharmazeutischer Verlag GmbH |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | curtin-20.500.11937-346602017-09-13T15:23:29Z Treatment of bone disorders with parathyroid hormone: Success and pitfalls Ng, P. Ong, A. Gale, L. Dass, Crispin Bone diseases such as osteoporosis, osteoarthritis, bone tumours and bone fractures are rather common and not just in the elderly. Parathyroid hormone (PTH) is responsible for maintaining calcium homeostasis, increasing bone mineral density (BMD), increasing cortical and trabecular bone thickness and thus increasing bone strength. Teriparatide (PTH 1-34) has the same effects as endogenous PTH and is pharmacologically used to treat bone diseases such as osteoporosis, osteoarthritis, bone fractures and bone tumours. This review discusses how PTH 1-34 plays a role in managing bone diseases. Clinical studies have shown that short or intermittent dosing of PTH 1-34 has minimal adverse effects, while long-term dosing (over two years) has been linked to de novo osteoarthritis and bone deformation. Currently PTH therapy is only approved in the treatment of post-menopausal osteoporosis, however it is also proven to have effects in treating osteoarthritis, bone tumours and bone fractures. If the patient undergoing therapy is closely monitored, the major pitfalls are very unlikely to take place, thus it is highly recommended that patients be closely monitored by a medical practitioner. 2016 Journal Article http://hdl.handle.net/20.500.11937/34660 10.1691/ph.2016.6008 Govi Verlag Pharmazeutischer Verlag GmbH restricted |
| spellingShingle | Ng, P. Ong, A. Gale, L. Dass, Crispin Treatment of bone disorders with parathyroid hormone: Success and pitfalls |
| title | Treatment of bone disorders with parathyroid hormone: Success and pitfalls |
| title_full | Treatment of bone disorders with parathyroid hormone: Success and pitfalls |
| title_fullStr | Treatment of bone disorders with parathyroid hormone: Success and pitfalls |
| title_full_unstemmed | Treatment of bone disorders with parathyroid hormone: Success and pitfalls |
| title_short | Treatment of bone disorders with parathyroid hormone: Success and pitfalls |
| title_sort | treatment of bone disorders with parathyroid hormone: success and pitfalls |
| url | http://hdl.handle.net/20.500.11937/34660 |